contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


aiforia-establishes-a-subsidiary-in-france

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analytiker

Frans-Mikael Rostedt

Head of Nordic ER Development, Analyst

Antti Luiro

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Jeg har set alle videoerne fra i år om Aiforia, og det gav et godt indtryk af en selvsikker direktør og et firma, der hele tiden vinder kunder. Ser man på markedet, er det i en rigtig god position, og når grundlaget for kundevækst er skabt, så skulle man tro, det ville give overskud.

Svært at sige hvor stor en handel det ville være. Jukka sagde efter min mening, at 1 er sikker, og den anden går måske til næste år? Mange handler går under informationsgrænsen.

Jeg venter med interesse på, om der kommer en forretningsmeddelelse via Siemens Healthineers inden årets udgang. Jukka Tapaninen sagde i et interview offentliggjort den 12.11, at han forventede 1-2 handler inden årets udgang, og som en ret stor aktør ville man dog forvente, at der ville være tale om en ret god nyhed vedrørende Aiforia, forhåbentlig skrider det gunstigt frem.

Der var ingen større ændringer i november måneds ejerliste, Heller ikke SEB’s nominee-register fortsatte salgene (-200k oktober, -400k september). Tidligere på året i april flyttede ca. 1800k fra SEB’s register til Citibanks register baseret på tallene.  Redigering: Det skal dog tilføjes, at SEB’s salgsprojekt naturligvis stadig kan være i gang, eller det kan være afsluttet. Sandsynligvis kender det såkaldte ‘smart money’ situationen via deres købstjenester, men for os ‘bullere’ (investorer med en bullish holdning) efterlader mørk handel, alternative handelspladser og hemmelighederne ved nominee-registre – som børsherrerne roser for at effektivisere markedets funktion – situationen til spekulation. Antageligt har SEB dog aktier fra flere kunder i depot, og en stor kunde kan af en eller anden grund have ønsket at reducere (sin beholdning).                    Aiforia              Aiforia - Osakkeenomistajat    Aiforia on lääketieteen ohjelmistoyritys, joka tarjoaa patologeille ja tutkijoille kliinisissä, prekliinisissä ja akateemisissa laboratorioissa tehokkaan syväoppivan tekoälyohjelmiston.

(Jeg har gennemgået årets tråde og fandt ikke et svar, så jeg tør spørge…) Aiforia forventes ifølge analytikerne (Luiro, Rostedt) at foretage aktieemissioner i '26 og '27. Er der

NuWays videointerview, der ligesom Inderes følger Aiforia. Jeg har ikke set det endnu.

Interview med Jukka, hentet fra LinkedIn:                   Choose Paris Region              Aiforia launches its AI hub in Paris Region    Founded in 2013, Aiforia is a pioneering healthtech company transforming medical imaging through artificial intelligence and deep learning. Headquartered in Helsinki, the company has rapidly become a reference in AI-powered image analysis, supporting...

Aiforia Technologies

Aiforia has had a sales organization in France since 2023, and the newly formed subsidiary will strengthen the company's local presence and support its growing business in the country. 

Translation: Original published in Finnish on 7/10/2025 at 9:30 am EEST.
Aiforia has had a sales organization in France since 2023, and the newly formed&#xa0;<a href="https://www.inderes.se/releases/aiforia-establishes-a-subsidiary-in-france-to-strengthen-its-position-in-the-european-market">subsidiary</a> will strengthen the company&apos;s local presence and support its growing business in the country. The new subsidiary will support Aiforia&apos;s growth and customer service in France and enable closer cooperation with local healthcare providers than before. According to the company, interest in its AI-based solutions has grown significantly in recent years, as evidenced by the <a href="https://www.inderes.se/en/analyst-comments/aiforias-collaboration-with-paris-hospital-district-moves-forward">Paris</a> and <a href="https://www.inderes.se/en/analyst-comments/aiforia-signs-new-clinical-account-in-france">Nantes</a> contracts. We believe the potential of these existing customers alone is significant if the expansion of customer partnerships is successful. France is investing heavily in the use of artificial intelligence in healthcare, and we expect Aiforia&apos;s business to expand significantly in France in the coming years. The launch of the subsidiary does not impact our view or the overall perception of the company, but we believe it bodes well for France&apos;s continued good progress in the future.

	2024	25e	26e
Omsætning	2,9	4,7	7,6
vækst-%	18,9 %	65,7 %	60,0 %
EBIT (adj.)	-12,2	-11,9	-12,0
EBIT-% (adj.)	-427,8 %	-252,9 %	-158,1 %
EPS (adj.)	-0,41	-0,37	-0,38
Udbytte	0,00	0,00	0,00
Udbytte %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.

Aiforia establishes a subsidiary in France

Key Estimate Figures23.04

Forumopdateringer